What is the appropriate initial dosing of Coumadin (warfarin) for adults, and how should the dose be adjusted for patients over 75 years, those with liver disease, low body weight, or interacting medications?

Coumadin Initial Dosing Recommendations

For most adults initiating warfarin, start with 5 mg daily; however, for patients ≥75 years old, use 2-4 mg daily as the initial dose to minimize bleeding risk and avoid over-anticoagulation. 1

Standard Adult Dosing (Age <75 years)

The FDA-approved initial dose is 2-5 mg once daily 1. In clinical practice, 5 mg is the preferred starting dose for most adults under 75 years 2. This approach:

• Avoids excessive early anticoagulation that occurs with 10 mg loading doses
• Prevents precipitous drops in protein C (which can create a transient hypercoagulable state)
• Results in fewer patients with INR >3.0 at 60 hours compared to 10 mg dosing 3

Avoid loading doses - routine use of loading doses (10 mg) increases hemorrhagic complications without providing faster therapeutic protection 1.

Elderly Patients (Age ≥75 years)

Start with 2-4 mg daily in elderly patients 1. The evidence strongly supports this:

• Patients ≥75 years require approximately 1 mg/day less than younger individuals to maintain comparable INR prolongation 4
• Among patients >70 years, the standard 5 mg/day dose will be excessive for 82% of women and 65% of men 5
• Elderly patients are more prone to bleeding even after controlling for anticoagulation intensity 4

The median weekly warfarin dose decreases by 0.4 mg per year of age 5.

Special Population Adjustments

Low Body Weight

• Weight <70 kg: Consider lower initial doses (2-4 mg daily)
• Lower weight is a protective factor against over-anticoagulation 6

Gender Considerations

• Women require 4.5 mg less per week than men (95% CI: 3.8-5.3 mg) 5
• Women ≥80 years have the lowest dose requirements: median 22 mg/week (3.1 mg/day) 5

Liver Disease

• Use lower initial doses (2-3 mg daily) in patients with hepatic impairment
• Warfarin metabolism is impaired, increasing bleeding risk
• Consider DOACs as alternatives in Child-Pugh class A cirrhosis, as they show reduced major bleeding risk compared to warfarin 7

Interacting Medications

Amiodarone: Significantly increases warfarin sensitivity - start with 2-2.5 mg daily and monitor closely 6

Antiplatelet agents (aspirin, NSAIDs): These double the bleeding risk (aHR 2.06) 8. If concurrent use is necessary:

• Use the lower end of initial dosing range
• Monitor INR more frequently
• Target INR 2.0-2.5 rather than 2.0-3.0 when possible

Monitoring Schedule

Initial phase (first 5-7 days):

• Check INR daily until stable 1
• Therapeutic INR typically achieved in 5-7 days 9

Stabilization phase (weeks 1-4):

• INR 2-3 times weekly for 1-2 weeks
• Then weekly for 1 month 9

Maintenance phase:

• INR every 1-4 weeks once stable 1
• Maximum interval: 4-6 weeks for patients with consistently stable INRs 2

Dose Adjustment Principles

When adjusting from initial dosing:

• Modify total weekly dose by 5-20% based on INR results 2
• Do not adjust for a single slightly out-of-range INR
• More frequent monitoring needed during medication changes, especially antibiotics 9

Critical Pitfalls to Avoid

1. Do not use 10 mg loading doses routinely - this causes 44% of patients to have INR >2.0 at 36 hours (vs 8% with 5 mg), with 36% having INR >3.0 at 60 hours 3

2. Do not use 5 mg in elderly patients - this will over-anticoagulate the majority of geriatric patients 5

3. Do not ignore concurrent antiplatelet therapy - this is an independent predictor of major bleeding (aHR 2.06) 8

4. Do not forget to reduce dose with amiodarone - amiodarone users are at significantly higher risk of over-anticoagulation 6

5. Do not use standard dosing in patients with varices - presence of esophageal/gastric varices increases major bleeding risk (aHR 2.31) 8